Control of spasticity in a multiple sclerosis model using central nervous system‐excluded CB 1 cannabinoid receptor agonists-Reference-Cited by-同舟云学术

Control of spasticity in a multiple sclerosis model using central nervous system‐excluded CB 1 cannabinoid receptor agonists

Published:2013-10-11 Issue:1 Volume:28 Page:117-130
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Pryce Gareth¹²,Visintin Cristina²³,Ramagopalan Sreeram V.¹,Al‐Izki Sarah¹,De Faveri Lia E.⁴,Nuamah Rosamond A.⁴,Mein Charles A.⁴,Montpetit Alexandre⁵,Hardcastle Alison J.⁶,Kooij Gijs⁷,Vries Helga E.⁷,Amor Sandra¹⁷,Thomas Sarah A.⁸,Ledent Catherine⁹,Marsicano Giovanni¹⁰,Lutz Beat¹¹,Thompson Alan J.²,Selwood David L.³,Giovannoni Gavin¹²,Baker David¹²

Affiliation:

1. Blizard InstituteQueen Mary University of LondonLondonUK

2. Institute of NeurologyUniversity College LondonLondonUK

3. Wolfson Institute for Biomedical ResearchUniversity College LondonLondonUK

4. Genome CentreBarts and the London School of Medicine and DentistryQueen Mary University of LondonLondonUK

5. McGill University and Genome Quebec Innovation CentreMontrealQuebecCanada

6. Institute of OphthalmologyUniversity College LondonLondonUK

7. Vrije Universiteit Medical CentreFree University of AmsterdamAmsterdamThe Netherlands

8. Institute of Pharmaceutical SciencesKings CollegeLondonUK

9. Institute of Interdisciplinary Research in Human and Molecular BiologyFree University of BrusselsBrusselsBelgium

10. Neurocentre Magendie, Institut National de la Santé et de la Recherche Médicale (INSERM)/University of BordeauxBordeauxFrance

11. Institute of Physiological ChemistryUniversity Medical Center of the Johannes Gutenberg University MainzMainzGermany

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.13-239442

Reference50 articles.

1. Multiple sclerosis;Compston A.;Lancet,2002

2. The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis

3. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

4. Cannabinoids control spasticity and tremor in a multiple sclerosis model

5. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cannabinoid CB₂ receptor orthologues; in vitro function and perspectives for preclinical to clinical translation;British Journal of Pharmacology;2023-08-04

2. Biosynthesis of cannabigerol and cannabigerolic acid: the gateways to further cannabinoid production;Synthetic Biology;2023-01-01

3. Treatment of spasticity;Handbook of Clinical Neurology;2023

4. Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty;Biology;2022-03-14

5. The cannabinoid agonist CB-13 produces peripherally mediated analgesia in mice but elicits tolerance and signs of central nervous system activity with repeated dosing;Pain;2021-12-27